David Cameron

66.2k total citations · 10 hit papers
533 papers, 23.8k citations indexed

About

David Cameron is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Cameron has authored 533 papers receiving a total of 23.8k indexed citations (citations by other indexed papers that have themselves been cited), including 329 papers in Oncology, 194 papers in Cancer Research and 157 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Cameron's work include Breast Cancer Treatment Studies (164 papers), HER2/EGFR in Cancer Research (138 papers) and Cancer Treatment and Pharmacology (133 papers). David Cameron is often cited by papers focused on Breast Cancer Treatment Studies (164 papers), HER2/EGFR in Cancer Research (138 papers) and Cancer Treatment and Pharmacology (133 papers). David Cameron collaborates with scholars based in United Kingdom, United States and France. David Cameron's co-authors include Giselle Mann, Graeme J. Hankey, Martine Piccart, J. Michael Dixon, Charles E. Geyer, Luca Gianni, Richard A. Anderson, Cristina Oliva, Steven Stein and W Jack and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

David Cameron

509 papers receiving 23.1k citations

Hit Papers

Lapatinib plus Capecitabine for HER2-Positive Advanced Br... 1999 2026 2008 2017 2006 2005 2010 2013 2017 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
    2006 2.5k citations Charles E. Geyer, Stephen Chan et al. profile →
  2. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
    2005 818 citations Martine Piccart, Nancy E. Davidson et al. JNCI Journal of the National Cancer Institute profile →
  3. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
    2010 777 citations David Cameron et al. European Journal of Cancer profile →
  4. The benefits and harms of breast cancer screening: an independent review
    2013 731 citations David Cameron et al. British Journal of Cancer profile →
  5. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
    2017 688 citations David Cameron, Martine Piccart et al. profile →
  6. Triple-negative breast cancer: disease entity or title of convenience?
    2010 652 citations Giuseppe Viale, David Cameron et al. profile →
  7. Swallowing Function After Stroke
    1999 624 citations David Cameron et al. profile →
  8. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial
    2015 600 citations David Cameron et al. profile →
  9. Identification of molecular apocrine breast tumours by microarray analysis
    2005 585 citations Hervé Bonnefoi, Gaëtan MacGrogan et al. profile →
  10. Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer
    2023 172 citations David Cameron et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Cameron United Kingdom 69 13.6k 7.0k 5.6k 4.8k 3.5k 533 23.8k
Fátima Cardoso Portugal 68 13.8k 1.0× 10.5k 1.5× 7.4k 1.3× 4.9k 1.0× 3.2k 0.9× 403 25.4k
Karen A. Gelmon Canada 73 15.9k 1.2× 7.0k 1.0× 5.6k 1.0× 6.6k 1.4× 2.6k 0.7× 393 23.8k
Julie R. Gralow United States 68 12.5k 0.9× 5.5k 0.8× 4.0k 0.7× 4.2k 0.9× 1.9k 0.5× 283 20.4k
Edith A. Perez United States 79 20.7k 1.5× 11.1k 1.6× 6.6k 1.2× 5.8k 1.2× 4.4k 1.3× 400 30.1k
Antonio C. Wolff United States 71 15.9k 1.2× 10.7k 1.5× 5.5k 1.0× 4.9k 1.0× 1.9k 0.5× 360 24.8k
George W. Sledge United States 72 14.8k 1.1× 9.6k 1.4× 7.5k 1.3× 6.3k 1.3× 1.7k 0.5× 444 25.4k
Jonas Bergh Sweden 73 15.6k 1.2× 11.6k 1.7× 11.2k 2.0× 4.9k 1.0× 3.3k 1.0× 521 29.1k
Lisa A. Carey United States 72 16.1k 1.2× 12.1k 1.7× 7.3k 1.3× 5.4k 1.1× 3.1k 0.9× 421 25.9k
Lisa M. McShane United States 65 12.7k 0.9× 10.9k 1.5× 9.1k 1.6× 5.1k 1.1× 2.2k 0.6× 184 28.1k
Carol DeSantis United States 32 13.0k 1.0× 6.4k 0.9× 7.8k 1.4× 5.1k 1.1× 2.0k 0.6× 55 28.2k

Countries citing papers authored by David Cameron

Since Specialization
Citations

This map shows the geographic impact of David Cameron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Cameron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Cameron more than expected).

Fields of papers citing papers by David Cameron

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Cameron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Cameron. The network helps show where David Cameron may publish in the future.

Co-authorship network of co-authors of David Cameron

This figure shows the co-authorship network connecting the top 25 collaborators of David Cameron. A scholar is included among the top collaborators of David Cameron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Cameron. David Cameron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Untch, Michael, David Pérol, Erica L. Mayer, et al.. (2024). Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis. European Journal of Cancer. 202. 113977–113977. 7 indexed citations
2.
Symeonides, Stefan N., Duncan Wheatley, Stephen Chan, et al.. (2023). Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Research and Treatment. 199(1). 35–46. 8 indexed citations
3.
Copson, Ellen, John E. Abraham, Jeremy Braybrooke, et al.. (2023). Expert UK consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: A modified Delphi panel. The Breast. 72. 103582–103582. 1 indexed citations
4.
Anderson, Richard A., David Cameron, Florian Clatot, et al.. (2022). Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Human Reproduction Update. 28(3). 417–434. 61 indexed citations
5.
Chatzipli, Aikaterini, Hervé Bonnefoi, Gaëtan MacGrogan, et al.. (2021). Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer. British Journal of Cancer. 125(10). 1356–1364. 2 indexed citations
6.
7.
Thomas, Jeremy, A M Hanby, Nicola S. Russell, et al.. (2017). The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer. Breast Cancer Research and Treatment. 163(1). 63–69. 14 indexed citations
8.
Bartlett, John M.S., Jane Bayani, Andrea Marshall, et al.. (2016). Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. JNCI Journal of the National Cancer Institute. 108(9). djw050–djw050. 148 indexed citations
9.
Schneider, Bryan P., Fei Shen, Laura Gardner, et al.. (2016). Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. Clinical Cancer Research. 23(1). 43–51. 66 indexed citations
10.
Metzger, Otto, Marion Procter, Evandro de Azambuja, et al.. (2013). Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. Journal of Clinical Oncology. 31(16). 1954–1960. 30 indexed citations
11.
Spears, Melanie, Karen J. Taylor, Alison F. Munro, et al.. (2011). In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Research and Treatment. 132(2). 463–470. 59 indexed citations
12.
13.
Blitz, Julia, et al.. (2010). Is temperament a key to the success of teaching innovation. African Journal of Health Professions Education. 2(1). 17–20. 1 indexed citations
14.
Scaltriti, Maurizio, Sarat Chandarlapaty, Ludmila Prudkin, et al.. (2010). Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clinical Cancer Research. 16(9). 2688–2695. 114 indexed citations
15.
McGlynn, Liane M., Tove Kirkegaard, Joanne Edwards, et al.. (2009). Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients. Clinical Cancer Research. 15(4). 1487–1495. 70 indexed citations
16.
Solessio, Eduardo, Yumiko Umino, David Cameron, et al.. (2009). Light Responses in Rods of Vitamin A–Deprived Xenopus. Investigative Ophthalmology & Visual Science. 50(9). 4477–4477. 3 indexed citations
17.
Press, Michael F., Richard S. Finn, David Cameron, et al.. (2008). HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer. Clinical Cancer Research. 14(23). 7861–7870. 134 indexed citations
18.
19.
Mullen, Peter, David Cameron, Max Hasmann, John F. Smyth, & Simon P. Langdon. (2007). Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Molecular Cancer Therapeutics. 6(1). 93–100. 50 indexed citations
20.
Cameron, David, et al.. (2004). Evidence for Multiple Roles of Müller Glia in the Regeneration of Adult Zebrafish Retina.. Investigative Ophthalmology & Visual Science. 45(13). 5344–5344. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fátima Cardoso Breakdown of academic impact, for papers by Karen A. Gelmon Breakdown of academic impact, for papers by Julie R. Gralow Breakdown of academic impact, for papers by Edith A. Perez Breakdown of academic impact, for papers by Antonio C. Wolff Breakdown of academic impact, for papers by George W. Sledge Breakdown of academic impact, for papers by Jonas Bergh Breakdown of academic impact, for papers by Lisa A. Carey Breakdown of academic impact, for papers by Lisa M. McShane Breakdown of academic impact, for papers by Carol DeSantis
Rankless by CCL
2026